Visit My NCBI to view a complete list of published work by Dr. Oehler.

20212020 | 2019 | 20182016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 20092007 | 2006 | 2005 | 2003


Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE.  Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 1;7(1):42-50.


Sari IN, Yang YG, Wijaya YT, Jun N, Lee S, Kim KS, Bajaj J, Oehler VG, Kim SH, Choi SY, Park SH, Kim DW, Reya T, Han J, Kwon HY.  AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth. Oncogene. 2020 Nov 17. doi: 10.1038/s41388-020-01547-x.

Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415.

Gerds AT, Gotlib J, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.  J Natl Compr Canc Netw. 2020 Sep;18(9):1248-1269.

Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020 Aug;34(8):2125-2137. PMCID: PMC7387243.

Palmieri R, Buckley SA, Othus M, Halpern AB, Percival MM, Scott, BL, Hendrie PC, Becker PS, Oehler VG, Estey EH, Walter RB. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. Leuk Lymphoma.  2020 Jul;61(7):1728-1731. PMCID: PMC7384960.

Hochhaus A, Gambacorti-Passerini C, Abboud C et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020 Aug;34(8):2125-2137. PMCID: PMC7387243.

Smith J, Ries R, Hylkema T, Alonzo T, Gerbing R…… Oehler V, Bolouri H and Meshinchi S.  Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options – COG and TARGET Pediatric AML Study.  Clinical Cancer Research. 2020, Feb 1;26(3):726-737.

Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB. Leukemia. 2020 Feb;34(2):635-639.


Houck K, Yuan H, Tian Y, Cramer D, Zhou A, Liu K, Zhou Z, Wu X, Zhang J, Oehler VG, and Dong JF.  Physical Proximity and Functional Cooperation of Glycoprotein 130 and Glycoprotein VI in Platelet Membrane Lipid Rafts.  J Thromb Haemost. 2019 Sep;17(9):1500-1510.

Godavarthy S, Herkt S, Weissenberger E, Aggoune D, Pan KT, Voutsinas JM, Wu Q, Muller MC, Oellerich T, Oehler VG, Van Etten RA, Lausen J, and Krause DS. The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. Haematologica. 2019 Apr 24. pii: haematol.2018.212365. doi: 10.3324/haematol.2018.212365.

Hoang VT, Verma D, Godvarthy PS, Llvona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Muller-Kuller U, Weissenberger E, Voutsinas JM, Oehler VG, Farin HF, Zornig M, Krause DS.  The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0358-8.


Gotlib J, Gerds AT, Bose P, et al.  Systemic Mastocytosis, version 2.2019, NCCN Clinical Practice Guidelines in Oncology.  J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537.

Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea, DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Shaik MN, Laird AD, O’Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results.  Am J Hematol. 2018 Nov; 93(11):  1301-1310.

*Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 May 15;24(10):2294-2303.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 Apr 2;18(1):359.

Lee SI, Celik S, Logsdon B, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, and Becker PS. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018 Jan 3;9(1):42.


Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, and Reya, T. CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. Cancer Cell. Published online November 14, 2016 as

Son HN, Srinivasan S, Yhee JY, Das D, Daugherty BK, Berguig GY, Oehler VG, Kim SH, Kim K, Kwon IC, Stayton PS, and Convertine AJ. Chemotherapeutic copolymers prepared via the RAFT polymerization of prodrug monomers. Polymer chemistry. 2016; 7 (27): 4494-4505.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, and Meshinchi S. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. Pediatr Blood Cancer. 2016; published on line August 11, 2016 as doi: 10.1002/pbc.26157.

Noren DP, Long BL, Norel R, Rrhissorrakrai K, Hess K, Hu CW, et al.  A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLOS Comput Biol. 2016; 12(6):e1004890.  PMCID: PMC4924788.

Brehme M, Koschmieder S, Montazeri M, Copland M, Oehler VG, Radich JP, Brummendorf TH, and Schuppert A. Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. Sci Rep. 2016; published online April 6, 2016 as doi: 10.1038/srep24057.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, Le Coutre P, Clark R, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW for the EPIC Investigators. Ponatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia: an International, Randomized, Open-Label, Phase 3 Trial. Lancet Oncology. 2016; 17(5): 612-621.

Soma L, Oehler VG, Ding C, and Cherian S. Small, abnormal B lymphoid blast populations in Chronic Myelogenous Leukemia at diagnosis: Does this finding indicate an accelerated course? Cytometry B Clin Cytom. 2016; published online January 21, 2016 as doi: 10.1002/cyto.b.21357.


*Morris VA, Cummings C, Korb B, Boaglio SM, and Oehler VG. Deregulated KLF4 expression in myeloid leukemias alters cell proliferation and differentiation through microRNA and gene targets. Mol Cell Biol. 2015 ; 36(4): 559. PMCID: PMC4751692.

Martinelli G, Oehler VG, Papayannnidis C, Courtney R, Shaik, NM, Zhang X, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematology. 2015; 2(8):e339-46.

Kwon HY, Bajaj J, Ito T, Blevins A, Konuma T, Weeks J, Lytle NK, Koechlein CS, Rizzieri D, Chuah C, Oehler VG, Sasik R, Hardiman G, and Reya T. Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. Cell Stem Cell. 2015; 17(2): 152-164.

Becker P, Huang J, Basu S, Zhao X, Chien S, Fang M, Oehler V, and Appelbaum F.  Mesenchymal Stromal Cells Derived from Acute Myeloid Leukemia Bone Marrow Exhibit Aberrant Cytogenetics and Cytokine Elaboration.  Blood Cancer J.  2015; 10(5):  e301. 

Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum F, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett AK, List AF, Fang M, Oehler V, Petersdorf SH, Pogosova-Agadjanyan E, Radich J, Willman CW, Meshinchi S, and Stirewalt D. Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: a SWOG and MRC/NCRI report. J Clin Oncol. 2015; 33(10):1157-64.


Zimdahl B, Ito T, Blevins A, Bajaj J, Konuma T, Weeks J, Koechlein CS, Kwon HY, Arami O, Rizzieri D, Broome HE, Chuah C, Oehler VG, Sasik R, Hardiman G, and Reya T. Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. Nat Genet. 2014; 46(3): 245-252.


Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, and Oehler VG. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells. 2013; PLOS One,8(9): e75815.

Cortes JE, Kim DW, Pinella-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Engl J Med. 2013; 369(19): 1783-1796 (PACE Investigator).

Pogosova-Agadjanyan E, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, Oehler VG, Petersdorf S, Radich JP, Willman CL, Meshinchi S, and Stirewalt DL.  The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.  2013; PLOS One, 8(8): e70812.


Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, and Oehler VG. Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. Bioinformatics. 2012; 28(6): 823-830.


Ho P, Kopecky K, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi S, Hirsch B, Oehler V, Hurwitz CA et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.  Blood. 2011; 118(17):  4561-4566.   

Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerma NA, Oehler V, et al. Higher dose imatinib for children with de novo chronic phase myelogenous leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011; 57(1): 56-62. PMID 21465636.

Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, et al.  The gamma catenin/CBP complex maintains survivin transcription in catenin deficient/depleted cancer cells.  Curr Cancer Drug Targets2011; 11(2):  213-225.  PMID 21158719.


Ito H, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento W, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich J, Jordan CT, and Reya T. Regulation of myeloid leukemia by the cell fate determinant Musashi. Nature. 2010; 466(7307): 765-768. PMID 20639863.

Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V et al. Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study. Leukemia2010; 24(5):  909-913.  PMID 20376086.


Oehler VG*, Yeung KY*, Choi YE, Bumgarner RE, Raftery AE, et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009; 114(15): 3292-3298. PMID 19654405. *Shared first author

Oehler VG, Guthrie K, Cummings CL, Sabo K, Wood BL, et al. Preferentially Expressed Antigen in Melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood. 2009;114(15): 3299-3308. PMID 19625708.

Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2009; 23(2): 396-399. PMID 18615105.


Oehler V and Radich JP.  Monitoring chronic myeloid leukemia in the age of tyrosine kinase inhibitors.  JNCCN. 2007; 5(5):  497-504. PMID 17509253.

Oehler V, Radich JP.  Monitoring of patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma. 2007; Suppl 2: S58-63.  PMID 17382014.

Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007; 109(4): 1782-1789. PMID 17062727.

Bonig H, Priestley GV, Oehler V, and Papayannopoulou T.  Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC.  Exp Hematol2007; 35(2):  326-334.  PMID 17258081.


Radich JP, Dai H, Mao M, Oehler V, Schelter J, et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia.  Proc Natl Acad Sci USA2006; 103(8):  2794-2799.  PMID 16477019.

Oehler VG, Radich JP.  Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.  Current hematologic malignancy reports. 2006; 1(3):152-9.


Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, et al. Randomized trial of allogeneic – related bone marrow transplantation vs. peripheral blood stem cell transplantation for chronic myeloid leukemia.  Biol Blood Marrow Tr. 2005; 11(2): 85-92. PMID 15682068.


Oehler VG, Radich JP.  Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. Curr Oncol Rep. 2003; 5(5): 426-35. PMID 12895396.